Abstract
The occurrence of drug-induced liver injury (DILI) after drug approval has often led to withdrawal from the market. Especially idiosyncratic DILI forms a major problem for pharmaceutical companies. Due to its independency of dose or duration of exposure, idiosyncratic DILI is considered as unpredictable. New in vitro test systems are now evoking to improve the prediction of DILI in the preclinical phase of drug development. Most conventional compound toxicity screening systems rely on single end-point assays most of which are based on relatively late-stage toxicity markers. When monitoring key events upstream in various adaptive stress signaling pathways combined in a single assay, the sensitivity to pick up hepatotoxic drugs will be increased while also mechanistic insight will be gained. Integrating with high-content imaging (HCI), time and high resolution single cell dynamics can be captured together with features for translocation between specific subcellular compartments. Efforts have been made to use specific dyes, antibodies or nanosensors in a multiplexed fashion using HCI, to assess multiple toxicity markers. However, these markers are still relatively downstream of toxicity signaling pathways which do not pinpoint to the molecular initiation event (MIE) of a drug. Here, we describe the application of a HepG2 BAC GFP reporter platform for the assessment of DILI liabilities by monitoring key components of adaptive stress pathways combining with HCI. Detailed insight in the regulation of these adaptive stress pathways during drug adversity can be reached by integrating these reporters with RNAi screening. Ultimately, this may lead to the recognition of novel biomarkers which can be used in the development of novel toxicity testing strategies.
Key words
- Systems microscopy
- Drug-induced liver injury
- Stress-response dynamics
- BAC-GFP reporter platform
- Mechanism-based toxicity screening
This is a preview of subscription content, access via your institution.
Buying options



References
Ostapowicz G, Fontana RJ, Schiødt FV et al (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137:947–954
Wilke R, Lin D, Roden D (2007) Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 6:904–916. https://doi.org/10.1038/nrd2423
Gu X, Manautou JE (2012) Molecular mechanisms underlying chemical liver injury. Expert Rev Mol Med 14:1–24. https://doi.org/10.1017/S1462399411002110
Simmons SO, Fan C-Y, Ramabhadran R (2009) Cellular stress response pathway system as a sentinel ensemble in toxicological screening. Toxicol Sci 111:202–225. https://doi.org/10.1093/toxsci/kfp140
Jennings P, Limonciel A, Felice L, Leonard MO (2013) An overview of transcriptional regulation in response to toxicological insult. Arch Toxicol 87:49–72. https://doi.org/10.1007/s00204-012-0919-y
Vinken M (2013) The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology 312:158–165. https://doi.org/10.1016/j.tox.2013.08.011
O’Brien PJ, Irwin W, Diaz D et al (2006) High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80:580–604. https://doi.org/10.1007/s00204-006-0091-3
Xu JJ, Henstock PV, Dunn MC et al (2008) Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105:97–105. https://doi.org/10.1093/toxsci/kfn109
Persson M, Løye AF, Mow T, Hornberg JJ (2013) A high content screening assay to predict human drug-induced liver injury during drug discovery. J Pharmacol Toxicol Methods 68:302–313. https://doi.org/10.1016/j.vascn.2013.08.001
Tolosa L, Pinto S, Donato MT et al (2012) Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol Sci 127:187–198. https://doi.org/10.1093/toxsci/kfs083
Zhang J, Doshi U, Suzuki A et al (2016) Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: results from 152 marketed drugs with known liver injury profiles. Chem Biol Interact 255:3–11. https://doi.org/10.1016/j.cbi.2015.11.008
Tolosa L, Carmona A, Castell JV et al (2015) High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins. Arch Toxicol 89:1847–1860. https://doi.org/10.1007/s00204-014-1334-3
Bauch C, Bevan S, Woodhouse H et al (2015) Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach. Toxicol In Vitro 29:621–630. https://doi.org/10.1016/j.tiv.2015.01.014
Germano D, Uteng M, Pognan F et al (2015) Determination of liver specific toxicities in rat hepatocytes by high content imaging during 2-week multiple treatment. Toxicol In Vitro 30:79–94. https://doi.org/10.1016/j.tiv.2014.05.009
van de Water FM, Havinga J, Ravesloot WT et al (2011) High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis. Toxicol In Vitro 25:1870–1882. https://doi.org/10.1016/j.tiv.2011.05.026
Lechner C, Reichel V, Moenning U et al (2010) Development of a fluorescence-based assay for drug interactions with human multidrug resistance related protein (MRP2; ABCC2) in MDCKII-MRP2 membrane vesicles. Eur J Pharm Biopharm 75:284–290. https://doi.org/10.1016/j.ejpb.2010.03.008
De Bruyn T, Sempels W, Snoeys J et al (2014) Confocal imaging with a fluorescent bile acid analogue closely mimicking hepatic taurocholate disposition. J Pharm Sci 103:1872–1881. https://doi.org/10.1002/jps.23933
Perlman ZE, Slack MD, Feng Y et al (2004) Multidimensional drug profiling by automated microscopy. Science 306(5699):1194–1198. https://doi.org/10.1126/science.1100709
Shuhendler AJ, Pu K, Cui L et al (2014) Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing. Nat Biotechnol 32:373–380. https://doi.org/10.1038/nbt.2838
Poon KL, Wang X, Lee SGP et al (2017) Transgenic Zebrafish reporter lines as alternative in vivo organ toxicity models. Toxicol Sci 156:133–148. https://doi.org/10.1093/toxsci/kfw250
Ray PD, Huang B-W, Tsuji Y (2012) Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 24:981–990. https://doi.org/10.1016/j.cellsig.2012.01.008
Hetz C (2012) The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol 13:89–102. https://doi.org/10.1038/nrm3270
Wink S, Hiemstra S, Huppelschoten S et al (2014) Quantitative high content imaging of cellular adaptive stress response pathways in toxicity for chemical safety assessment. Chem Res Toxicol 27:338–355. https://doi.org/10.1021/tx4004038
Banin S, Moyal L, Shieh S-Y et al (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674–1677. https://doi.org/10.1126/science.281.5383.1674
Varfolomeev E, Vucic D (2016) Intracellular regulation of TNF activity in health and disease. Cytokine. https://doi.org/10.1016/j.cyto.2016.08.035
Jaeschke H, McGill MR, Ramachandran A (2012) Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev 44:88–106. https://doi.org/10.3109/03602532.2011.602688
Liu J, Wu KC, Lu YF et al (2013) NRF2 protection against liver injury produced by various hepatotoxicants. Oxidative Med Cell Longev 2013:305861. https://doi.org/10.1155/2013/305861
Enomoto A, Itoh K, Nagayoshi E et al (2001) High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 59:169–177
Qu Q, Liu J, Zhou HH, Klaassen CD (2014) Nrf2 protects against furosemide-induced hepatotoxicity. Toxicology 324:35–42. https://doi.org/10.1016/j.tox.2014.02.008
Puthalakath H, O’Reilly LA, Gunn P et al (2007) ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129:1337–1349. https://doi.org/10.1016/j.cell.2007.04.027
Yamaguchi H, Wang HG (2004) CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 279:45495–45502. https://doi.org/10.1074/jbc.M406933200
Hur KY, So J-S, Ruda V et al (2012) IRE1α activation protects mice against acetaminophen-induced hepatotoxicity. J Exp Med 209:307–318. https://doi.org/10.1084/jem.20111298
Uzi D, Barda L, Scaiewicz V et al (2013) CHOP is a critical regulator of acetaminophen-induced hepatotoxicity. J Hepatol 59:495–503. https://doi.org/10.1016/j.jhep.2013.04.024
Yu J, Zhang L (2003) No PUMA, no death: implications for p53-dependent apoptosis. Cancer Cell 4:248–249. https://doi.org/10.1016/S1535-6108(03)00249-6
Fredriksson L, Herpers B, Benedetti G et al (2011) Diclofenac inhibits tumor necrosis factor-α-induced nuclear factor-κB activation causing synergistic hepatocyte apoptosis. Hepatology 53:2027–2041. https://doi.org/10.1002/hep.24314
Poser I, Sarov M, JR a H et al (2008) BAC TrangeneOmics: a high-throughput method for exploration of protein function in mammals. Nat Methods 5:409–415. https://doi.org/10.1038/nmeth.1199
Wink S, Hiemstra S, Herpers B, van de Water B (2017) High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol 91:1367–1383. https://doi.org/10.1007/s00204-016-1781-0
Igarashi Y, Nakatsu N, Yamashita T et al (2015) Open TG-GATEs: a large-scale toxicogenomics database. Nucleic Acids Res 43:D921–D927. https://doi.org/10.1093/nar/gku955
Suter L, Schroeder S, Meyer K et al (2011) EU framework 6 project: predictive toxicology (PredTox)-overview and outcome. Toxicol Appl Pharmacol 252:73–84. https://doi.org/10.1016/j.taap.2010.10.008
Chen M, Vijay V, Shi Q et al (2011) FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 16:697–703. https://doi.org/10.1016/j.drudis.2011.05.007
Jiang X, Wink S, van de Water B, Kopp-schneider A (2016) Functional analysis of high-content high-throughput imaging data. J Appl Stat 44:1903–1919. https://doi.org/10.1080/02664763.2016.1238048
Herpers B, Wink S, Fredriksson L et al (2016) Activation of the Nrf2 response by intrinsic hepatotoxic drugs correlates with suppression of NF-κB activation and sensitizes toward TNFα-induced cytotoxicity. Arch Toxicol 90:1163–1179. https://doi.org/10.1007/s00204-015-1536-3
Fredriksson L, Wink S, Herpers B et al (2014) Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFα-mediated hepatotoxicity. Toxicol Sci 140:144–159. https://doi.org/10.1093/toxsci/kfu072
Sutherland JJ, Jolly RA, Goldstein KM, Stevens JL (2016) Assessing concordance of drug-induced transcriptional response in rodent liver and cultured hepatocytes. PLoS Comput Biol 12:1–31. https://doi.org/10.1371/journal.pcbi.1004847
Carreras Puigvert J, von Stechow L, Siddappa R et al (2013) Systems biology approach identifies the kinase csnk1a1 as a regulator of the DNA damage response in embryonic stem cells. Sci Signal 6:ra5. https://doi.org/10.1126/scisignal.2003208
LeCluyse EL, Witek RP, Andersen ME, Powers MJ (2012) Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 42:501–548. https://doi.org/10.3109/10408444.2012.682115
Ramaiahgari SC, den Braver MW, Herpers B et al (2014) A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies. Arch Toxicol 88:1083–1095. https://doi.org/10.1007/s00204-014-1215-9
Hiemstra S, Wink S, van den Nieuwendijk K, Ramaiaghari S, Dankers A, de Bont H and van de Water B. A 3D HepG2 GFP reporter platform to screen for drug-induced liver injury liabilities. Manuscript in preparation
Hiemstra S, Niemeijer M, Koedoot E et al (2016) Comprehensive landscape of Nrf2 and p53 pathway activation dynamics by oxidative stress and DNA damage. Chem Res Toxicol 30:923–933. https://doi.org/10.1021/acs.chemrestox.6b00322
Jennen DGJ, Magkoufopoulou C, Ketelslegers HB et al (2010) Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci 115:66–79. https://doi.org/10.1093/toxsci/kfq026
Bader A (2003) Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos 31:1035–1042
Gómez-Lechón MJ, Tolosa L, Donato MT (2016) Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs. J Appl Toxicol 36:752–768. https://doi.org/10.1002/jat.3277
Amacher DE (2012) The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury. Expert Opin Drug Metab Toxicol 8:335–347. https://doi.org/10.1517/17425255.2012.658041
Leung L, Kalgutkar AS, Obach RS (2012) Metabolic activation in drug-induced liver injury. Drug Metab Rev 44:18–33. https://doi.org/10.3109/03602532.2011.605791
Jinek M, East A, Cheng A et al (2013) RNA-programmed genome editing in human cells. elife 2:e00471. https://doi.org/10.7554/eLife.00471
Cong L, Ran FA, Cox D et al (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823. https://doi.org/10.1126/science.1231143
Gómez-Lechón MJ, Tolosa L (2016) Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening. Arch Toxicol 90:2049–2061. https://doi.org/10.1007/s00204-016-1756-1
Gao X, Liu Y (2017) A transcriptomic study suggesting human iPSC-derived hepatocytes potentially offer a better in vitro model of hepatotoxicity than most hepatoma cell lines. Cell Biol Toxicol 33:407–421. https://doi.org/10.1007/s10565-017-9383-z
Asplund A, Pradip A, van Giezen M et al (2016) One standardized differentiation procedure robustly generates homogenous hepatocyte cultures displaying metabolic diversity from a large panel of human pluripotent stem cells. Stem Cell Rev Rep 12:90–104. https://doi.org/10.1007/s12015-015-9621-9
Raju R, Chau D, Cho DS et al (2017) Cell expansion during directed differentiation of stem cells toward the hepatic lineage. Stem Cells Dev 26:274–284. https://doi.org/10.1089/scd.2016.0119
Chen Y-F, Tseng C-Y, Wang H-W et al (2012) Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology 55:1193–1203. https://doi.org/10.1002/hep.24790
Ware BR, Berger DR, Khetani SR (2015) Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes. Toxicol Sci 145:252–262. https://doi.org/10.1093/toxsci/kfv048
Acknowledgments
This work was supported by the FP7 DETECTIVE project (grant agreement 266838), IMI MIP-DILI project (grant agreement 115336), and the H2020 EU-ToxRisk project (grant agreement 681002).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Niemeijer, M., Hiemstra, S., Wink, S., den Hollander, W., ter Braak, B., van de Water, B. (2018). Systems Microscopy Approaches in Unraveling and Predicting Drug-Induced Liver Injury (DILI). In: Chen, M., Will, Y. (eds) Drug-Induced Liver Toxicity. Methods in Pharmacology and Toxicology. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-7677-5_29
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7677-5_29
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-7676-8
Online ISBN: 978-1-4939-7677-5
eBook Packages: Springer Protocols